What one share of Celldex Therapeutics holds
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.
Celldex Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$4.34 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$3.49 |
| Cash and investments | $9.14 |
| Book value | $9.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $11.49 | −$27.64 | $0.40 | −$23.00 | — | $55.82 |
| 2010 | $22.03 | −$1.19 | $0.99 | −$15.28 | — | $35.21 |
| 2011 | $3.52 | −$17.01 | $0.19 | −$13.73 | — | $23.32 |
| 2012 | $2.91 | −$15.37 | $0.08 | −$13.02 | — | $22.32 |
| 2013 | $0.77 | −$15.33 | $0.79 | −$13.52 | — | $53.75 |
| 2014 | $0.60 | −$19.81 | $0.32 | −$17.36 | — | $35.44 |
| 2015 | $0.85 | −$19.66 | $0.75 | −$16.04 | — | $44.10 |
| 2016 | $1.00 | −$18.99 | $0.41 | −$17.11 | — | $33.04 |
| 2017 | $1.49 | −$10.86 | $0.21 | −$11.87 | — | $25.60 |
| 2018 | $0.91 | −$14.48 | $0.08 | −$7.28 | — | $10.38 |
| 2019 | $0.25 | −$3.51 | $0.05 | −$3.25 | — | $5.54 |
| 2020 | $0.25 | −$2.02 | $0.05 | −$1.42 | — | $5.29 |
| 2021 | $0.11 | −$1.64 | $0.03 | −$1.45 | — | $8.98 |
| 2022 | $0.05 | −$2.40 | $0.04 | −$2.25 | — | $6.91 |
| 2023 | $0.14 | −$2.92 | $0.04 | −$2.25 | — | $7.68 |
| 2024 | $0.11 | −$2.45 | $0.03 | −$2.48 | — | $11.25 |
| 2025 | $0.02 | −$3.90 | $0.04 | −$3.22 | — | $7.92 |
Common questions about Celldex Therapeutics
How much does one share of Celldex Therapeutics earn?
Over the last 12 months, Celldex Therapeutics lost $4.34 for each share on $0.00 of sales.
Does Celldex Therapeutics pay a dividend?
Celldex Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Celldex Therapeutics’s book value per share?
Celldex Therapeutics’s book value is $9.10 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Celldex Therapeutics have?
Each share of Celldex Therapeutics has $9.14 of cash and investments, as of June 30, 2026.
What is Celldex Therapeutics’s free cash flow per share?
−$3.49 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Celldex Therapeutics bought back shares?
Celldex Therapeutics’s share count rose about 4926% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.